Introduction
Sp4 is a transcription factor that recognizes GC-rich sequences in the "CpG islands" around the promoters of many genes (Heisler et al., 2005) . In contrast to the Sp1 gene, Sp4 gene expression is restricted to neuronal cells in the brain (Supp et al., 1996; Zhou et al., 2005) . Our previous studies found that Sp4 hypomorphic mice displayed several behavioral phenotypes relevant to psychiatric disorders, including deficits in prepulse inhibition and hypersensitivity to ketamine (Zhou et al., 2005 (Zhou et al., , 2007 (Zhou et al., , 2010 . In humans, the SP4 gene was reported to be sporadically deleted in patients with schizophrenia (Tam et al., 2010; Zhou et al., 2010) , and the SP4 protein is reduced in the post-mortem brains of bipolar patients (Pinacho et al., 2011) . Additionally, human genetic studies reported the association of the SP4 gene with bipolar disorder, schizophrenia, and major depression (Shyn et al., 2009; Zhou et al., 2009; Shi et al., 2010; Greenwood et al., 2011) . These studies suggest the Sp4 hypomorphic mice as a promising mouse genetic model for human psychiatric disorders.
Administration of ketamine, a noncompetitive N-methyl-Daspartate (NMDA) receptors antagonist, induces behaviors that resemble several aspects of psychiatric disorders in healthy people (Krystal et al., 1994; Xu et al., 2015) . Prolonged ketamine effects and exacerbation of symptoms were reported in schizophrenia patients after administration of ketamine (Lahti et al., 1995; Malhotra et al., 1997; Holcomb et al., 2005) . On the other hand, ketamine was recently found to act as a potent antidepressant that provides rapid relief to patients who are resistant to treatment with classical antidepressants (Zarate et al., 2006; Price et al., 2009; aan het Rot et al., 2010; Diazgranados et al., 2010; Li et al., 2010) . In rodents, ketamine also disrupts prepulse inhibition of startle (PPI), a form of sensorimotor gating that is deficient in patients with either schizophrenia or bipolar disorder, but not in patients with depression (Braff et al., 2001; Geyer, 2006) . It is unclear however, what genes and neurons are the key regulators of such responses to ketamine.
Sp4 hypomorphic mice have robust behavioral phenotypes such as deficient PPI and hypersensitivity to ketamine-induced hyperlocomotion (Ji et al., 2013) . By taking advantage of a genetic rescue strategy used in the generation of Sp4 hypomorphic mice (Zhou et al., 2005) , we restored Sp4 expression in forebrain excitatory and GABAergic inhibitory neurons, respectively. Deficient PPI and ketamine-induced hyperlocomotion were examined in the two different neuron-specific Sp4 rescue mouse lines.
Materials and Methods

Mouse Strains and Breeding
Following the recommendation of the Banbury Conference on Genetic Background in Mice (Banbury, 1997) to use the F1 genetic background, we generated Sp4 hypomorphic mice on an F1 129S/Black Swiss genetic background for behavioral studies, as previously described (Ji et al., 2013) . The Emx1-Cre mouse line (stock number: 005628) and Dlx6a-Cre mouse line (stock number: 008199) were purchased from Jackson laboratory. Both lines were backcrossed with Black Swiss mice for more than six generations. Each Cre line was then bred with Sp4 heterozygous mice on a Black Swiss background to obtain double heterozygous mice. The double heterozygous mice were finally bred with Sp4 heterozygous mice on a 129S background to obtain F1 generation mice ( Figure 1S ). All F1 Sp4 heterozygous mice were sacrificed, and the remaining four genotypes were used for molecular and behavioral analyses (Supplemental Table I ). Mice were housed in a climate-controlled animal colony with a reversed day/night cycle. Food (Harlan TeklabI) and water were available ad libitum, except during behavioral testing. Behavioral testing began when mice were 3 months old with PPI and ketamine-induced locomotor activity tests separated by at least 2 weeks. All testing procedures were approved by the UCSD Animal Care and Use Committee (permit number: A3033-01) prior to the onset of the experiments. Mice were maintained in American Association for Accreditation of Laboratory Animal Care-approved animal facilities at UCSD and the local Veteran's Administration Hospital. These facilities meet all Federal and State requirements for animal care.
LacZ Staining
20 µm thick cryostat sections were cut from fresh adult mouse brains. The sections were fixed, permeabilized, and stained as previously described (Zhou et al., 2005) .
Western Blot
Total protein was extracted from mouse cortices and striata and Western blot analyses were subsequently performed as described (Ji et al., 2014) . Anti-Sp4 antibody was purchased from Santa Cruz Biotechnology (sc-13019, sc-645).
Immunohistochemical Analysis
Adult mice were anesthetized with carbon dioxide, and perfused transcardially with 2% phosphate buffered saline paraformaldehyde. Mouse brains were dissected out and further fixed in 4% paraformaldehyde solution at 4°C for 24 hrs. Paraffin sections were generated. Sequential chromogenic immunohistochemistry was conducted to examine the colocalization of Sp4 protein with Gad67 protein, a marker for GABAergic neurons in mouse cortex, as described by Kim et al. (2012) .
Prepulse Inhibition
Startle reactivity and prepulse inhibition (PPI) were measured with startle chambers (SR-LAB, San Diego Instruments) as described by Ji et al. (2013) . The background noise level was 65 dB, and the pulse was 120 dB for 40 ms. The prepulse intensities were 69, 73, and 81 dB (4, 8, and 16 dB above the 65-dB background noise, respectively), delivered 80 ms before the pulse.
The test session began and ended with five presentations of the "pulse-alone" trial. In between, each acoustic or "no stimulus" (65 dB background noise only) trial type was presented ten times in a pseudo-random order. The amount of PPI was calculated as a percentage score for each acoustic prepulse trial: %PPI = 100% × {1 -[(Startle response for "prepulse + pulse")/(Startle response for "pulse-alone")]}.
Video-Tracking Locomotion Tests
Locomotor activity was measured using the Video-Tracker (VT) system as previously described (Ji et al., 2013) . Mice were tested during their dark period with lights on for the entire duration of the test. They were first acclimated to the testing room for 60 min. Then, they were placed into white plastic enclosures (41 × 41 × 34 cm 3 ), surrounded by an opaque plastic curtain. A video camera, mounted 158 cm above the enclosures, generated the signal for the Polytrack digitizer (San Diego Instruments). The position of each animal (x, y; in pixels) was sampled with a frequency of 18.18 Hz, which was used to generate a coordinate file (x, y, t) consisting of the x-location, y-location, and the duration (time t) spent in that location. After acclimation, mice were placed in their enclosures for 30 min of habituation. They then received ketamine (described below) and were placed back in their enclosures for another 60 min.
Ketamine
Ketamine was dissolved in saline and administered i.p. at a volume of 5 ml/kg after 30 min habituation in the VT arena (Brody et al., 2003) . The doses of ketamine were determined from the same F1 genetic background mouse in previous studies (Ji et al., 2013) . A within-subjects crossover design was used for drug studies, with 2 weeks between drug treatments.
Statistical Analysis
Repeated measures analysis of variance with genotype as a between-subjects factor and drug treatment, block, and prepulse intensity as within-subjects factors were performed on the %PPI data and total distance traveled. Post hoc analyses were carried out using Newman-Keuls or Tukey's test. Alpha level was set to 0.05. No outliers were detected or removed from the analysis. All statistical analyses were carried out using the BMDP statistical software (Statistical Solutions Inc.).
Results
Generation of Neuron-Specific Sp4 Rescue Mice
Mouse Emx1 (Briata et al., 1996) and Dlx5/6 (Robledo et al., 2002) expression are first detected at embryonic day 9.5 (E9.5) and E8.5, respectively. Forebrain excitatory neurons originate from the Emx1 cell lineage (Gorski et al., 2002) , while forebrain GABAergic neurons are derived from the Dlx5/6 cell lineage (Monory et al., 2006) . Since mouse Sp4 expression starts around E9.5 (Supp et al., 1996) , the Cre driven by Emx1 and Dlx5/6 genes will restore the Sp4 gene during the entire development of forebrain excitatory and GABAergic neurons, respectively. In F1 Sp4 homozygous mice carrying either the Emx1-Cre or Dlx6a-Cre (Dlx5/6-Cre) gene ( Figure S1 ), the nuclear LacZ cassette was excised to restore Sp4 expression in each cell lineage (Figure 1 ). Consistent with previous reports on Emx1-Cre expression (Gorski et al., 2002) , introduction of Emx1-Cre into Sp4 heterozygous mice abolished LacZ staining in both cortical and hippocampal excitatory neurons ( Figure 1A) . Under higher magnification, many LacZ blue spots remained in both the cortex and hippocampus. They presumably consisted of GABAergic and other types of neurons ( Figure 1B) ] rescue mice (Figure 2A) . Restoration of the Sp4 transcription factor was also confirmed in the striata of [Sp4
Hypo/Hypo
; Tg(Dlx6a-Cre)] rescue mice ( Figure 2B ). An increased level of Sp4 protein was observed in the cortices of GABAergic Sp4 rescue mice [Sp4 Tg(Dlx6a-Cre)], we conducted sequential immunohistochemical analyses of Sp4 and Gad67 proteins (Kim et al., 2012) . Sp4 protein was detected only in the Gad67-positive GABAergic interneurons in the Sp4 rescue mice carrying the Dlx6a-Cre gene ( Figure 2C ). There is no detectable Sp4 protein in the surrounding Gad67-negative neurons, which are mostly cortical excitatory neurons. In contrast, most cortical neurons, except Gad67-positive interneurons, express Sp4 protein in the Sp4 rescue mice carrying the Emx1-Cre gene.
Behavioral Characterization of the Emx1-Cre Rescue Mice
Deficits in PPI and ketamine-induced hyperlocomotion were examined in the two different neuron-specific Sp4 rescue mice. In the Emx1-Cre rescue cohort, startle reactivity (Supplemental Table II ) and PPI (Supplemental Table III and IV) were investigated. Sp4 hypomorphic mice showed significantly reduced PPI [F(1,80)=18.23, p < 0.0001; Figure 3A] ] rescue mice [Sp4 X Emx1-Cre interaction, F(1,80) < 1, ns]. No sex effects were observed. We examined the locomotor response of these mice to ketamine (50 mg/kg) using video-tracking (VT) equipment. Before ketamine treatment, there was no significant Sp4 gene effect on distance traveled during habituation. After ketamine injection, Sp4 hypomorphic mice exhibited significantly more ketamine-induced hyperactivity compared to wild-type controls {Figure 3B; Sp4 X ketamine interaction [F(1,79)= 12.97, p = 0.0006] on distance traveled}. No Sp4 X Emx1-Cre X ketamine interaction was detected [F(1,79) < 1, ns]. ) Sp4 hypomorphic mice after ketamine injection, suggesting that there was no rescue of ketamine hypersensitivity.
Behavioral Characterization of the Dlx6a-Cre Rescue Mice
In the Dlx6a-Cre rescue cohort, startle reactivity (Supplemental Table V ) and PPI (Supplemental Table VI and VII) were investigated. Sp4 hypomorphic mice exhibited reduced PPI [F(1,85) = 9.73, p = 0.002; Figure 4A ]. However, no Sp4 X Dlx6a-Cre interaction was detected [F(1,85) Figure 4B ). Interestingly, there was a significant Sp4 X Dlx6a-Cre X ketamine interaction [F(1,85)=7.44, p = 0.008]. ; Tg(Dlx6a-Cre)] after ketamine injection, suggesting that restoration of Sp4 in forebrain GABAergic neurons is sufficient to rescue ketamine-induced hyperlocomotion in Sp4 hypomorphic mice.
Discussion
Genetic manipulations are powerful tools for disentangling complex phenotypic profiles. We previously demonstrated that a full restoration of the Sp4 gene in the whole animal by crossing with a protamine-cre mouse line rescued the complete phenotypic profile seen in Sp4 hypomorphic mice (Zhou et al., 2005) . Conventional and conditional gene-knockout strategies can determine whether a gene is necessary for a particular phenotype in a specific type of cells. Conditional rescue of a phenotype in knockout mice via restoration of the gene in only one specific cell type can determine whether the gene in that specific cell type is necessary and sufficient for controlling the phenotype. Many behaviors are complex, and likely modulated by interactions between different types of neurons from different brain regions. Given that different types of neurons are involved in the modulation of behavior, it is not surprising that Sp4 gene restoration in only one specific type of neuron may not be sufficient to rescue the full behavioral profile. Indeed, we failed to rescue deficient PPI in Sp4 hypomorphic mice regardless of whether the Sp4 gene was restored in forebrain excitatory neurons or GABAergic neurons, although PPI was rescued previously when the Sp4 gene was rescued in the whole animal (Zhou et al., 2005) . Importantly, however, we found that restoration of the Sp4 gene in GABAergic neurons was sufficient to rescue ketamineinduced hyperlocomotion in the Sp4 hypomorphic mice.
Sp4 hypomorphic mice (Sp4
Hypo/Hypo
) from the Dlx6a-Cre rescue cohort displayed a prolonged response to ketamine relative to the response in wild-type control mice. However, Sp4 hypomorphic mice (Sp4 ) from the Emx1-Cre rescue cohort had a similar time-course response to ketamine with their sibling wild-type mice. The prolonged response to ketamine in the Sp4 hypomorphic mice from the Dlx6a-Cre rescue cohort is a more typical response of Sp4 hypomorphic mice according to our previous studies (Ji et al., 2013) . Why did the same dosage of ketamine not elicit a prolonged response to ketamine in the Sp4 hypomorphic mice from the Emx1-Cre rescue cohort? We speculate that there may be still subtle differences between the genetic backgrounds of the Emx1-Cre and Dlx6a-Cre mouse lines despite the fact that both Emx1-Cre and Dlx6a-Cre mouse lines were backcrossed for more than six generations. The genetic background of the Emx1-Cre rescue cohort may have been overall less sensitive to ketamine than that of the Dlx6a-Cre rescue cohort. We consider that different time-course responses to ketamine may be generated by differential ketamine sensitivities between mouse cohorts or different dosages of ketamine. Indeed, increasing dosages of ketamine produced more locomotor activity and prolonged responses (Irifune et al., 1991) . This observation may explain why the same dosage of ketamine generated different time-courses in the locomotor responses between the two different mouse cohorts.
Ketamine acts primarily, although not exclusively (Kapur and Seeman, 2002) , as a noncompetitive antagonist of NMDA receptors that are present in both excitatory and GABAergic neurons in multiple brain regions. Cortical GABAergic inhibitory neurons have been suggested to be the primary targets of NMDA receptor antagonists (Moghaddam et al., 1997; Homayoun and Moghaddam, 2007) . Our studies suggest that the mouse Sp4 gene is essential for forebrain GABAergic neurons to dampen locomotor responses to ketamine. Reduced Sp4 expression may impair the ability of GABAergic neurons to control locomotor hyperactivity in Sp4 hypomorphic mice after ketamine injection (Ji et al., 2013) . In contrast, the Sp4 gene expression appears dispensable in excitatory neurons in controlling the locomotor response to ketamine. Since the genetic restoration of the Sp4 gene in Dlx6a-Cre lineage cells starts from early embryogenesis, our studies cannot differentiate whether altered development and/ or function of forebrain GABAergic neurons are responsible for ketamine hypersensitivity in Sp4 hypomorphic mice. Although we did not find gross abnormalities in the brains of Sp4 hypomorphic mice (Zhou et al., 2005; Ji et al., 2013) , we cannot rule out subtle structural alterations in GABAergic neurons. As for molecular mechanisms, the NMDA receptor has been proposed as the primary target of ketamine. The protein, but not mRNA, of Nmdar1, the obligatory subunit of NMDA receptors, was down-regulated in the brains of Sp4 hypomorphic mice (Zhou et al., 2010; Sun et al., 2015) . Those findings, however, came from mouse brain tissue that contained different types of neurons and glial cells, and hence do not necessarily exclude the Nmdar1 gene as a direct target of the Sp4 transcription factor in a small group of specific neurons. There is still a possibility that the Sp4 transcription factor may directly regulate mRNA expression of the Nmdar1 gene in some forebrain GABAergic neurons (Krainc et al., 1998) . Forebrain GABAergic neurons consist of striatal neurons and different cortical GABAergic neurons. It remains to be investigated which subset of GABAergic neurons is responsible for the rescue effects observed here. Investigation of molecular mechanisms can eventually be conducted after identification of the critical GABAergic neurons. It should be kept in mind that other receptors and channels, in addition to NMDA receptors, may also mediate the effects of ketamine in Sp4 hypomorphic mice (Jamie Sleigha et al., 2014) . In the future, restoration of the Sp4 gene in forebrain GABAergic neurons via temporal and region-specific (e.g. cortex or striatum) control of Cre-mediated DNA recombination may clarify the role of development of GABAergic neurons and functions of regional GABAergic neurons in controlling locomotor responses to ketamine.
Cortical GABAergic inhibitory interneurons have been proposed to be the primary targets of NMDA receptor antagonists (Moghaddam et al., 1997; Homayoun and Moghaddam, 2007) and contribute to the pathogenesis of schizophrenia (Lewis et al., 2005; Lewis and Moghaddam, 2006) . Abnormalities in GABA receptors have been reported in the brains of patients with schizophrenia, bipolar disorder, or major depression (Fatemi et al., 2013) . Ketamine produces schizophrenia-like behavioral phenotypes in healthy people and exacerbates symptoms in schizophrenia patients. Our studies suggest that SP4, deleted in some patients with schizophrenia, could be a missing piece that links a genetic susceptibility gene with ketamine hypersensitivity and abnormal function of GABAergic neurons in schizophrenia. The influence of the Sp4-GABAergic-ketamine pathway may not be limited to the regulation of locomotor activity in response to ketamine. Given that ketamine functions as a potent antidepressant, it will be interesting to investigate whether the Sp4-GABAergic-NMDA pathway may also be involved in the regulation of depressive behaviors. Indeed, our most recent studies suggested that Sp4 hypomorphic mice displayed depressive-like behaviors (Young et al., 2015) . In the future, such depressivelike phenotypes will be examined after ketamine treatment in Sp4 hypomorphic mice with restoration of the Sp4 gene in GABAergic neurons.
